Saturday, May 4, 2024

Vogon Today

Selected News from the Galaxy

StartMag

Novartis slams against the government on Mes and Covid

3 years ago babelfish

Novartis slams against the government on Mes and Covid

Here are criticisms and whispers of the pharmaceutical giant Novartis in government on Mes and beyond

Digital innovation, access to medicines and, above all, strengthening of the NHS: a better healthcare, in Italy, now struggling with the Covid emergency (and with all the dysfunctions), is possible. It would be enough to really want it, for Novartis. And direct the money of Mes, which the government does not use, and the Recovery Fund well.

Here are all the puffs of the pharmaceutical giant Novartis towards Palazzo Chigi.

NOVARTIS INVOKES THE MONTH

Let's start with the auspices. Novartis calls for a sanitary mes for Italy against government wait-and-seeism.

"The discussions on the ESM appear out of time: 37 billion euros immediately available (but still firm) of which instead there is a huge need to support healthcare personnel and for digital transformation", writes Pasquale Frega, president of Novartis Italia and CEO of Novartis Farma, in a speech on MF-Milano Finanza.

THE OPPORTUNITY OF RECOVERY FUND

Not only Mes. Italy could and should seize the opportunities of the Recovery Fund to improve the health sector.

A NATIONAL INSTITUTE FOR DIGITAL HEALTH AND CARE

And it is Mes and Recovery Fund that could contribute to the birth – as the group of European and Japanese multinationals of Farmindustria, underlines Frega – "of a national institute for Health and Digital Care that can help with projects at the highest level the digital transition of healthcare in connected rate ".

NOVARTIS: 250 MILLION IN THREE YEARS

Even Novartis, waiting for the government to decide on how to spend the money, will still do its part and promises to invest 50 million for the next three years in clinical research, as announced by Frega himself during a virtual meeting with the press on the occasion of the digital event “Dialogue matters. Restarting from health to build tomorrow's sustainable society together ", in which the pharmaceutical multinational presented the results of the" Materiality Analysis ", carried out in collaboration with The European House – Ambrosetti to identify the priority themes for the investments of the next three years.

WHAT TO INVEST IN

What should we invest in, therefore, in Italy? On a more digital healthcare and more attentive to the needs of patients. And it is for this reason that in addition to clinical research, Novartis investments will aim at increasing patient services and guaranteeing simple access to medicines, digital innovation but also correct communication.

This is a machine translation from Italian language of a post published on Start Magazine at the URL https://www.startmag.it/sanita/novartis-sbrocca-contro-il-governo-su-mes-e-covid/ on Tue, 01 Dec 2020 11:00:27 +0000.